In Vitro Diagnostics (IVD) / Medical Devices - Point-of-Care and Specimen Collection
Strategic Profile
The company reported Q4 2025 revenue of $26.8 million with management pointing to early signs of stabilization across key end markets after a transition year marked by a challenging funding environment. Executives highlighted two mid-year 2026 product launches as near-term growth catalysts, following FDA submissions made in December. Entering 2026, the company is seeing "increasing signs of stability in key segments," including improved visibility to funding for testing and research programs.
Cyborg Score Rationale
The company scores low due to weak financial performance (losses and challenged cash flow) and bearish technical momentum, with offsetting factors including a strong balance sheet and potentially positive FDA-related product catalysts. Full 2025 revenue fell 38% to $115.0 million, though stabilization signs are emerging in 2026.
Top Insights
Two FDA applications submitted in December for rapid molecular OTC self-test for chlamydia/gonorrhea (Sherlock) and Colli-Pee at-home urine collection device, targeting mid-year launches with CT/NG TAM of >$1.5 billion.
International diagnostics trends are stabilizing with nearshoring (in-country assembly in Africa) expected to contribute revenue in Q1 and throughout 2026.
Sample management business positioned to deliver growth in 2026 as genomic end markets stabilize and gradually return to stronger growth driven by precision medicine adoption.
Most recent acquisition of BioMedomics completed November 5, 2025, expanding sickle cell disease diagnostic capabilities internationally.